Schiff Hardin Wins Trial in Pharmaceutical Patent Infringement Litigation for Lupin Ltd.
- Client: Lupin Ltd.
- Date: 2010 - 2012
- Location: U.S. District Court for the District of New Jersey
After a six-day bench trial, a Schiff Hardin team prevailed for client Lupin Ltd. in a Hatch-Waxman pharmaceutical patent litigation involving Teva Women's Health's Seasonique® oral contraceptive regimen. On Friday, June 29, 2012, Judge Peter Sheridan of the United States District Court for the District of New Jersey ruled for our client, Lupin Ltd., and invalidated U.S. Patent No. 7,320,969 ("the '969 patent") covering Seasonique® as obvious under the clear and convincing evidence standard. See Teva Women's Health, Inc., v. Lupin, Ltd., Civil Action No. 10-603, 2012 U.S. Dist. LEXIS 90698 (D.N.J. June 29, 2012).
Teva Women's Health filed a patent infringement action against our client Lupin in January 2010 after Lupin filed an abbreviated new drug application with the FDA to sell a generic version of Seasonique® in late 2009.